Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Arbutus Biopharma Corporation Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 01, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update July 18, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels June 06, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure June 05, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Participate in Jefferies Global Healthcare Conference May 29, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Present Imdusiran Data at EASL Congress 2024 May 22, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Participate in Two Upcoming Investor Conferences May 07, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update May 02, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 May 02, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update April 18, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna April 04, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Participate in Two Upcoming Investor Conferences March 08, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update February 29, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update February 15, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Announces 2024 Corporate Objectives and Provides Financial Update January 08, 2024 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® November 09, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS BRNS Arbutus to Present at Jefferies London Healthcare Conference November 08, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Announces CEO, William Collier, to Retire December 31, 2023 November 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update October 24, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference October 18, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023 October 11, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended September 11, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Participate in Two Upcoming Investor Conferences September 07, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update August 03, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update July 20, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors July 12, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Arbutus Appoints Two New Executives July 10, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS BMY KRYS NBRV Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody June 21, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS VACC Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 June 21, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Tickers ABUS Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.